View our earnings forecast for Cara Therapeutics. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Mani Mohindru, and Scott Terrillion. You may vote once every thirty days. Cara Therapeutics, Inc. is a biopharmaceutical company.
Wall Street analysts are rating CARA a Strong Buy today.
Want to see which stocks are moving? Zacks Style Scores Education - Learn more about the Zacks Style Scores. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. Medallia Stock: Time to Pounce on Underappreciated Digital Cloud Play? The company is focused on developing and commercializing new chemical entities designed to alleviate pain.
Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. How to buy Cara Therapeutics stock | $13.73, finder.com is a financial comparison and information service, not a bank or An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Applying this theory in practice suggests that $42.00 is a viable price objective for Cara Therapeutics stock. The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. View which stocks are hot on social media with MarketBeat's trending stocks report. 69.73% of the stock of Cara Therapeutics is held by institutions. Get the latest Cara Therapeutics Inc CARA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Even the slightest mention of the words “marijuana,” “cannabis,” “THC,” or “cannabidiol (CBD)” in a press release creates a massive buzz around a stock. Cara Therapeutics's fiscal year ends in December. We may also receive compensation if you click on certain links posted on our site.
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders. High Tide Inc: Overlooked Pot Stock Just Reported Some Big News, Digital Turbine Inc: Mobile App Stock up 810% Since March, But Not Done Yet, MIND C.T.I.
3 Oversold Stocks That Could Bounce Back in a Hurry, Pfizer (NYSE:PFE) Stock: A Strong Option for Dividend Investors. Learn everything you need to know about successful options trading with this three-part video course. Greed and the fear of missing out (FOMO) is causing retail investors to clamor into this space. Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter. Visit performance for information about the performance numbers displayed above. Please appreciate that there may be other options available to you than the products, providers or services covered by our service. Learn about financial terms, types of investments, trading strategies and more. Specifically, they have bought $0.00 in company stock and sold $136,766.00 in company stock. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. View real-time stock prices and stock quotes for a full financial overview. The middle trough, the head, is always the largest. In layman’s terms, this means Cara Therapeutics’ drug treatment uses the non-psychoactive property of marijuana that is alleged to have many medical and health benefits. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. What is Cara Therapeutics's CUSIP number? No part of this document may be used or reproduced in any manner or means, including print, electronic, mechanical, or by any information storage and retrieval system whatsoever, without written permission from the copyright holder. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. A bubble may be in the making, but this is not necessarily bad news.